Thrombocytopenia associated with chronic liver disease

Related Experiment Video

Updated: Jul 5, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
08:45

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation

Published on: June 27, 2025

Nezam Afdhal1, John McHutchison, Robert Brown

  • 1Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. nafdhal@bidmc.harvard.edu

Journal of Hepatology
|April 25, 2008
PubMed

Insights

Thrombocytopenia, a low platelet count, affects many with chronic liver disease (CLD). New treatments targeting thrombopoietin (TPO) show promise for increasing platelet levels and improving patient care.

Area of Science:

  • Hepatology
  • Hematology
  • Pharmacology

Background:

  • Thrombocytopenia (platelet count <150,000/microL) is a frequent complication in chronic liver disease (CLD), affecting up to 76% of patients.
  • Moderate thrombocytopenia (50,000-75,000/microL) occurs in about 13% of cirrhosis patients.
  • Contributing factors include splenic sequestration, bone marrow suppression, and interferon therapy, with potential roles for thrombopoietin (TPO) reduction.

Purpose of the Study:

  • To review the impact of thrombocytopenia on CLD patient management.
  • To explore the potential of novel therapeutic agents for managing thrombocytopenia in CLD.
  • To highlight agents that stimulate TPO and increase platelet counts.

Main Methods:

  • Literature review of thrombocytopenia in CLD.
  • Analysis of factors contributing to low platelet counts.
  • Evaluation of emerging treatments, including thrombopoietin receptor agonists.

Main Results:

  • Thrombocytopenia significantly complicates routine care, delaying procedures like liver biopsy and surgery.
  • Novel agents, such as eltrombopag, are being developed to increase platelet levels.
  • These agents aim to reduce reliance on platelet transfusions and facilitate necessary medical treatments.

Conclusions:

  • Effective therapies to raise platelet counts in CLD patients are needed.
  • Novel TPO-stimulating agents offer a promising avenue for managing thrombocytopenia.
  • Successful treatment could significantly improve the management and outcomes for patients with CLD.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...